Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-09-22

AUTHORS

Tsuyoshi Nozue, Hiroaki Hattori, Kazuyuki Ogawa, Takeshi Kujiraoka, Tadao Iwasaki, Tsutomu Hirano, Ichiro Michishita

ABSTRACT

BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein (LDL) cholesterol levels. Recently, PCSK9 has additionally been related to metabolic risk factors such as the levels of triglycerides, apolipoprotein B (apoB), insulin, and glucose, as well as body mass index. The purpose of this study was to investigate correlations between serum levels of PCSK9 and apoB-containing atherogenic lipoproteins in patients with coronary artery disease (CAD).MethodsSerum levels of PCSK9 and lipoprotein(a) [Lp(a)]; small, dense LDL; and oxidized LDL were measured in 101 patients with CAD who were not receiving lipid-lowering therapy.ResultsSerum hetero-dimer PCSK9 levels were positively correlated with serum levels of Lp(a) (r = 0.195, p = 0.05); small, dense LDL (r = 0.336, p = 0.0006); and oxidized LDL (r = 0.268, p = 0.008). Multivariate regression analyses showed that serum hetero-dimer PCSK9 was a significant predictor of serum levels of Lp(a) (β = 0.235, p = 0.01); small, dense LDL (β = 0.143, p = 0.03); and oxidized LDL (β = 0.268, p = 0.008).ConclusionsSerum PCSK9 levels were positively correlated with serum levels of Lp(a); small, dense LDL; and oxidized LDL in patients with CAD. This suggests that the interaction between serum PCSK9 and apoB-containing lipoproteins plays a role in establishing the atherosclerotic status of patients.Trial registrationUMIN Clinical Trials Registry, UMIN ID: C000000311. More... »

PAGES

165

References to SciGraph publications

  • 2016-02-19. Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese in JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8

    DOI

    http://dx.doi.org/10.1186/s12944-016-0339-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1046753598

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/27658826


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1101", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical Biochemistry and Metabolomics", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan", 
              "id": "http://www.grid.ac/institutes/grid.417368.f", 
              "name": [
                "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nozue", 
            "givenName": "Tsuyoshi", 
            "id": "sg:person.01033145125.12", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033145125.12"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410848.1", 
              "name": [
                "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hattori", 
            "givenName": "Hiroaki", 
            "id": "sg:person.01306227053.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306227053.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410848.1", 
              "name": [
                "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ogawa", 
            "givenName": "Kazuyuki", 
            "id": "sg:person.01022006542.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022006542.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410848.1", 
              "name": [
                "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kujiraoka", 
            "givenName": "Takeshi", 
            "id": "sg:person.01130141300.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130141300.55"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410848.1", 
              "name": [
                "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Iwasaki", 
            "givenName": "Tadao", 
            "id": "sg:person.0751577337.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751577337.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.410714.7", 
              "name": [
                "Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hirano", 
            "givenName": "Tsutomu", 
            "id": "sg:person.016274235662.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016274235662.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan", 
              "id": "http://www.grid.ac/institutes/grid.417368.f", 
              "name": [
                "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Michishita", 
            "givenName": "Ichiro", 
            "id": "sg:person.0732262025.70", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s40618-016-0433-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052469678", 
              "https://doi.org/10.1007/s40618-016-0433-9"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2016-09-22", 
        "datePublishedReg": "2016-09-22", 
        "description": "BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein (LDL) cholesterol levels. Recently, PCSK9 has additionally been related to metabolic risk factors such as the levels of triglycerides, apolipoprotein B (apoB), insulin, and glucose, as well as body mass index. The purpose of this study was to investigate correlations between serum levels of PCSK9 and apoB-containing atherogenic lipoproteins in patients with coronary artery disease (CAD).MethodsSerum levels of PCSK9 and lipoprotein(a) [Lp(a)]; small, dense LDL; and oxidized LDL were measured in 101 patients with CAD who were not receiving lipid-lowering therapy.ResultsSerum hetero-dimer PCSK9 levels were positively correlated with serum levels of Lp(a) (r\u2009=\u20090.195, p\u2009=\u20090.05); small, dense LDL (r\u2009=\u20090.336, p\u2009=\u20090.0006); and oxidized LDL (r\u2009=\u20090.268, p\u2009=\u20090.008). Multivariate regression analyses showed that serum hetero-dimer PCSK9 was a significant predictor of serum levels of Lp(a) (\u03b2\u2009=\u20090.235, p\u2009=\u20090.01); small, dense LDL (\u03b2\u2009=\u20090.143, p\u2009=\u20090.03); and oxidized LDL (\u03b2\u2009=\u20090.268, p\u2009=\u20090.008).ConclusionsSerum PCSK9 levels were positively correlated with serum levels of Lp(a); small, dense LDL; and oxidized LDL in patients with CAD. This suggests that the interaction between serum PCSK9 and apoB-containing lipoproteins plays a role in establishing the atherosclerotic status of patients.Trial registrationUMIN Clinical Trials Registry, UMIN ID: C000000311.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s12944-016-0339-8", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1031029", 
            "issn": [
              "1476-511X"
            ], 
            "name": "Lipids in Health and Disease", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "15"
          }
        ], 
        "keywords": [
          "proprotein convertase subtilisin/kexin type 9", 
          "coronary artery disease", 
          "convertase subtilisin/kexin type 9", 
          "subtilisin/kexin type 9", 
          "serum levels", 
          "dense LDL", 
          "artery disease", 
          "PCSK9 levels", 
          "atherogenic lipoproteins", 
          "serum low-density lipoprotein cholesterol levels", 
          "type 9", 
          "low-density lipoprotein cholesterol levels", 
          "serum proprotein convertase subtilisin/kexin type 9", 
          "lipid-lowering therapy", 
          "metabolic risk factors", 
          "lipoprotein cholesterol levels", 
          "Clinical Trials Registry", 
          "body mass index", 
          "levels of triglycerides", 
          "multivariate regression analysis", 
          "atherosclerotic status", 
          "MethodsSerum levels", 
          "Trials Registry", 
          "mass index", 
          "cholesterol levels", 
          "risk factors", 
          "apolipoprotein B", 
          "patients", 
          "LDL", 
          "lipoprotein", 
          "significant predictors", 
          "regression analysis", 
          "disease", 
          "key regulator", 
          "levels", 
          "registry", 
          "therapy", 
          "triglycerides", 
          "insulin", 
          "trials", 
          "predictors", 
          "glucose", 
          "correlation", 
          "status", 
          "index", 
          "factors", 
          "study", 
          "role", 
          "regulator", 
          "purpose", 
          "analysis", 
          "ID", 
          "interaction"
        ], 
        "name": "Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease", 
        "pagination": "165", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1046753598"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s12944-016-0339-8"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "27658826"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s12944-016-0339-8", 
          "https://app.dimensions.ai/details/publication/pub.1046753598"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T17:05", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_715.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s12944-016-0339-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    165 TRIPLES      21 PREDICATES      79 URIs      70 LITERALS      7 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s12944-016-0339-8 schema:about anzsrc-for:11
    2 anzsrc-for:1101
    3 schema:author N0fa4304729cd453dbbe47a72389cc8c0
    4 schema:citation sg:pub.10.1007/s40618-016-0433-9
    5 schema:datePublished 2016-09-22
    6 schema:datePublishedReg 2016-09-22
    7 schema:description BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein (LDL) cholesterol levels. Recently, PCSK9 has additionally been related to metabolic risk factors such as the levels of triglycerides, apolipoprotein B (apoB), insulin, and glucose, as well as body mass index. The purpose of this study was to investigate correlations between serum levels of PCSK9 and apoB-containing atherogenic lipoproteins in patients with coronary artery disease (CAD).MethodsSerum levels of PCSK9 and lipoprotein(a) [Lp(a)]; small, dense LDL; and oxidized LDL were measured in 101 patients with CAD who were not receiving lipid-lowering therapy.ResultsSerum hetero-dimer PCSK9 levels were positively correlated with serum levels of Lp(a) (r = 0.195, p = 0.05); small, dense LDL (r = 0.336, p = 0.0006); and oxidized LDL (r = 0.268, p = 0.008). Multivariate regression analyses showed that serum hetero-dimer PCSK9 was a significant predictor of serum levels of Lp(a) (β = 0.235, p = 0.01); small, dense LDL (β = 0.143, p = 0.03); and oxidized LDL (β = 0.268, p = 0.008).ConclusionsSerum PCSK9 levels were positively correlated with serum levels of Lp(a); small, dense LDL; and oxidized LDL in patients with CAD. This suggests that the interaction between serum PCSK9 and apoB-containing lipoproteins plays a role in establishing the atherosclerotic status of patients.Trial registrationUMIN Clinical Trials Registry, UMIN ID: C000000311.
    8 schema:genre article
    9 schema:isAccessibleForFree true
    10 schema:isPartOf N14cf3a76c53845f38cafc53a48b99028
    11 Nac4bd09be2d54b579bb7acc40699b26f
    12 sg:journal.1031029
    13 schema:keywords Clinical Trials Registry
    14 ID
    15 LDL
    16 MethodsSerum levels
    17 PCSK9 levels
    18 Trials Registry
    19 analysis
    20 apolipoprotein B
    21 artery disease
    22 atherogenic lipoproteins
    23 atherosclerotic status
    24 body mass index
    25 cholesterol levels
    26 convertase subtilisin/kexin type 9
    27 coronary artery disease
    28 correlation
    29 dense LDL
    30 disease
    31 factors
    32 glucose
    33 index
    34 insulin
    35 interaction
    36 key regulator
    37 levels
    38 levels of triglycerides
    39 lipid-lowering therapy
    40 lipoprotein
    41 lipoprotein cholesterol levels
    42 low-density lipoprotein cholesterol levels
    43 mass index
    44 metabolic risk factors
    45 multivariate regression analysis
    46 patients
    47 predictors
    48 proprotein convertase subtilisin/kexin type 9
    49 purpose
    50 registry
    51 regression analysis
    52 regulator
    53 risk factors
    54 role
    55 serum levels
    56 serum low-density lipoprotein cholesterol levels
    57 serum proprotein convertase subtilisin/kexin type 9
    58 significant predictors
    59 status
    60 study
    61 subtilisin/kexin type 9
    62 therapy
    63 trials
    64 triglycerides
    65 type 9
    66 schema:name Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
    67 schema:pagination 165
    68 schema:productId N0c6722ab7b944a1da8ec197045e295f6
    69 N897c8088380040b3921e7d5e7ed73143
    70 Nd096d35c5f164fd6aa13982a3356b30f
    71 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046753598
    72 https://doi.org/10.1186/s12944-016-0339-8
    73 schema:sdDatePublished 2022-08-04T17:05
    74 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    75 schema:sdPublisher Nddf313b1533a4cb5a645ffea6bf53dc2
    76 schema:url https://doi.org/10.1186/s12944-016-0339-8
    77 sgo:license sg:explorer/license/
    78 sgo:sdDataset articles
    79 rdf:type schema:ScholarlyArticle
    80 N086ba986de5441d59d7515b5cef63db1 rdf:first sg:person.01130141300.55
    81 rdf:rest N71bac8ffd5b84dc8af9b76cd486410f9
    82 N0c6722ab7b944a1da8ec197045e295f6 schema:name pubmed_id
    83 schema:value 27658826
    84 rdf:type schema:PropertyValue
    85 N0fa4304729cd453dbbe47a72389cc8c0 rdf:first sg:person.01033145125.12
    86 rdf:rest Nb3ef967aa3ae4fe3a978da773ace24fe
    87 N14cf3a76c53845f38cafc53a48b99028 schema:issueNumber 1
    88 rdf:type schema:PublicationIssue
    89 N3cbc6449c88b477387d74b4c1d0a7b09 rdf:first sg:person.01022006542.43
    90 rdf:rest N086ba986de5441d59d7515b5cef63db1
    91 N71bac8ffd5b84dc8af9b76cd486410f9 rdf:first sg:person.0751577337.13
    92 rdf:rest Na01ee64f9b194f06965820179390b2e1
    93 N72a9af86b99444e9a9417eccb07afdbf rdf:first sg:person.0732262025.70
    94 rdf:rest rdf:nil
    95 N897c8088380040b3921e7d5e7ed73143 schema:name doi
    96 schema:value 10.1186/s12944-016-0339-8
    97 rdf:type schema:PropertyValue
    98 Na01ee64f9b194f06965820179390b2e1 rdf:first sg:person.016274235662.39
    99 rdf:rest N72a9af86b99444e9a9417eccb07afdbf
    100 Nac4bd09be2d54b579bb7acc40699b26f schema:volumeNumber 15
    101 rdf:type schema:PublicationVolume
    102 Nb3ef967aa3ae4fe3a978da773ace24fe rdf:first sg:person.01306227053.48
    103 rdf:rest N3cbc6449c88b477387d74b4c1d0a7b09
    104 Nd096d35c5f164fd6aa13982a3356b30f schema:name dimensions_id
    105 schema:value pub.1046753598
    106 rdf:type schema:PropertyValue
    107 Nddf313b1533a4cb5a645ffea6bf53dc2 schema:name Springer Nature - SN SciGraph project
    108 rdf:type schema:Organization
    109 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    110 schema:name Medical and Health Sciences
    111 rdf:type schema:DefinedTerm
    112 anzsrc-for:1101 schema:inDefinedTermSet anzsrc-for:
    113 schema:name Medical Biochemistry and Metabolomics
    114 rdf:type schema:DefinedTerm
    115 sg:journal.1031029 schema:issn 1476-511X
    116 schema:name Lipids in Health and Disease
    117 schema:publisher Springer Nature
    118 rdf:type schema:Periodical
    119 sg:person.01022006542.43 schema:affiliation grid-institutes:grid.410848.1
    120 schema:familyName Ogawa
    121 schema:givenName Kazuyuki
    122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022006542.43
    123 rdf:type schema:Person
    124 sg:person.01033145125.12 schema:affiliation grid-institutes:grid.417368.f
    125 schema:familyName Nozue
    126 schema:givenName Tsuyoshi
    127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033145125.12
    128 rdf:type schema:Person
    129 sg:person.01130141300.55 schema:affiliation grid-institutes:grid.410848.1
    130 schema:familyName Kujiraoka
    131 schema:givenName Takeshi
    132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130141300.55
    133 rdf:type schema:Person
    134 sg:person.01306227053.48 schema:affiliation grid-institutes:grid.410848.1
    135 schema:familyName Hattori
    136 schema:givenName Hiroaki
    137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306227053.48
    138 rdf:type schema:Person
    139 sg:person.016274235662.39 schema:affiliation grid-institutes:grid.410714.7
    140 schema:familyName Hirano
    141 schema:givenName Tsutomu
    142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016274235662.39
    143 rdf:type schema:Person
    144 sg:person.0732262025.70 schema:affiliation grid-institutes:grid.417368.f
    145 schema:familyName Michishita
    146 schema:givenName Ichiro
    147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70
    148 rdf:type schema:Person
    149 sg:person.0751577337.13 schema:affiliation grid-institutes:grid.410848.1
    150 schema:familyName Iwasaki
    151 schema:givenName Tadao
    152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751577337.13
    153 rdf:type schema:Person
    154 sg:pub.10.1007/s40618-016-0433-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052469678
    155 https://doi.org/10.1007/s40618-016-0433-9
    156 rdf:type schema:CreativeWork
    157 grid-institutes:grid.410714.7 schema:alternateName Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan
    158 schema:name Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan
    159 rdf:type schema:Organization
    160 grid-institutes:grid.410848.1 schema:alternateName Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan
    161 schema:name Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan
    162 rdf:type schema:Organization
    163 grid-institutes:grid.417368.f schema:alternateName Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan
    164 schema:name Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan
    165 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...